Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Solid Support for Flu Vaccine Development

This article was originally published in Start Up

Executive Summary

Vaccines generally are one of the few areas in pharmaceutical development where government incentives, science, and intellectual property are in alignment to favor commercialization. This is particularly true for flu vaccine, where recent events have drawn the attention of government and Big Pharma. That, plus the advent of new adjuvant technology and innovative manufacturing methods, signals opportunity for new players.

You may also be interested in...



Use of canine cells in flu vaccine development debated

The Vaccines and Related Biological Products Advisory Committee will discuss the use of Madin-Darby canine kidney cells in the manufacturing of live attenuated influenza virus vaccines. When the committee met in 2005 to discuss using the cells, it overwhelmingly agreed that companies should move forward with development, but also recommended that studies be done in animals inoculated with the final vaccine product (1"The Pink Sheet," Nov. 21, 2005, p. 22). It also recommended monitoring patients because of potential oncogenic risks from the tumorigenic canine cell lines

Flu Vaccine Production In 2008 Will Match 2007, But Strains Get Overhaul

The U.S. influenza vaccine market appears stable in terms of the amount of available product, but the nature of the product this year will be quite different

Finding Human Monoclonals for Infectious Disease Vaccines

A recent publication shows the ability to make high-affinity, virus-specific human monoclonal antibodies in a matter of weeks from antibody-secreting plasma cells. The research suggests, at least theoretically, that an antibody vaccine could be developed for any infectious disease, using blood from either immunized or infected individuals.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL026487

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel